Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志
中国生物工程杂志  2017, Vol. 37 Issue (3): 1-9    DOI: 10.13523/j.cb.20170301
研究报告     
EGF类生长因子来源的新型靶向肽在抗肿瘤药物蛋白中的应用
陈坤1, 曹雪玮1, 张琴2, 赵健1, 王富军2,3
1. 华东理工大学生物反应器工程重点实验室 上海 200237;
2. 浙江日升昌药业有限公司 东阳 322100;
3. 上海中医药大学中药研究所 上海 201203
Application of EGF-like Growth Factor-derived Tumor-homing Peptide for Antineoplastic Protein
CHEN Kun1, CAO Xue-wei1, ZHANG Qin2, ZHAO Jian1, WANG Fu-jun2,3
1. State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China;
2. Zhejiang Reachall Pharmaceutical Co. Ltd, Dongyang 322100, China;
3. Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
 全文: PDF(2000 KB)   HTML
摘要：

许多肿瘤细胞表面表皮生长因子受体EGFR都存在过表达现象。考察了牛痘病毒生长因子（VGF）中的EGFR结合域（S3）与人的肝素样表皮生长因子（HB-EGF）来源的肝素结合域（命名为HE）重组后对肿瘤细胞的选择性。通过重组表达带有靶向和穿膜结构域的EGFP-S3-HE和EGFP-S3-HE-TATm两种融合蛋白与正常细胞和肿瘤细胞的共孵育实验来研究其对肿瘤细胞的特异性靶向吸附和穿膜效应。进一步将S3-HE-TATm靶向穿膜序列与苦瓜来源的核糖体失活蛋白MAP30融合，可显著提高MAP30对肿瘤细胞的抑杀作用，但这种抑杀作用却对正常细胞仍保持在较低水平。由此表明S3-HE-TATm是一种新型优异的肿瘤细胞靶向药物运输载体，可用于肿瘤治疗的进一步开发研究。
关键词： 肿瘤靶向肽;  牛痘病毒生长因子;  细胞穿膜肽;  表皮生长因子;  抗肿瘤药物    
Abstract:

Many studies have showed epidermal growth factor receptors (EGFR) were overexpressed in various types of cancer cells. The S3, an EGFR-binding domain derived from vaccinia virus growth factor (VGF), when fused to HE, a heparin binding domain derived from heparin-binding epidermal growth factor (HB-EGF),could enhance its tumor-homing ability. The incubation experiment of the fusion protein EGFP-S3-HE/EGFP-S3-HE-TATm (TAT is cell penetrating peptide) with normal/tumor cells proved that both the recombinant proteins had tumor cell specific targeting ability and significant penetrating effect.The fusion of S3-HE-TATmwith MAP30, a ribosome inactivation protein derived from Momordica charantia, significantly increased the inhibitory effect of MAP30 to tumor cells but still remained relatively low level effect to normal cells, Therefore, S3-HE-TATm is a new type of drug delivery vector for tumor targeting treatment.
Key words: Tumor-homing peptide    Epidermal growth factor    Anti-tumor drug    VGF    Cell penetrating peptides
收稿日期: 2016-11-20 出版日期: 2017-03-25
ZTFLH:  Q71  
基金资助:

国家自然科学基金资助项目（81171449）
通讯作者: 赵健     E-mail: zhaojian@ecust.edu.cn
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　

引用本文:

陈坤, 曹雪玮, 张琴, 赵健, 王富军. EGF类生长因子来源的新型靶向肽在抗肿瘤药物蛋白中的应用[J]. 中国生物工程杂志, 2017, 37(3): 1-9.

CHEN Kun, CAO Xue-wei, ZHANG Qin, ZHAO Jian, WANG Fu-jun. Application of EGF-like Growth Factor-derived Tumor-homing Peptide for Antineoplastic Protein. China Biotechnology, 2017, 37(3): 1-9.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20170301    或    https://manu60.magtech.com.cn/biotech/CN/Y2017/V37/I3/1

[1] Xue Y J, Han X H, Chen D Y, et al. Effects of recombinant MAP30 on cell proliferation and apoptosis of human esophageal carcinoma EC-1.71 cells. African Journal of Pharmacy & Pharmacology, 2011, 5(24):2680-2688.
[2] Koren E, Torchilin V P. Cell-penetrating peptides:breaking through to the other side. Trends in Molecular Medicine, 2012, 18(7):385-393.
[3] Fang S, Fan T, Fu H W, et al. A novel cell-penetrating peptide derived from human eosinophil cationic protein. PLoS One, 2013, 8(3):e57318-e57318.
[4] Yoon J S, Jung Y T, Hong S K, et al. Characteristics of HIV-TAT protein transduction domain. Journal of Microbiology, 2004, 42(4):328-335.
[5] Svensen N, Walton J G A, Bradley M. Peptides for cell-selective drug delivery. Trends in Pharmacological Sciences, 2012, 33(4):186-192.
[6] Tebbutt N, Pedersen M W, Johns T G. Targeting the ERBB family in cancer:couples therapy. Nature Reviews Cancer, 2013, 13(9):663-673.
[7] Tan M, Lan K H, Yao J, et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Research, 2006, 66(7):3764-3772.
[8] Long T N, Yang X Z, Du X, et al. Enhancing tumor-specific intracellular delivering efficiency of cell-penetrating peptide by fusion with a peptide targeting to EGFR. Amino Acids, 2015, 47(5):1-10.
[9] Hynes N E, Lane H A. ERBB receptors and cancer:the complexity of targeted inhibitors. Nature Reviews Cancer, 2005, 5(5):341-354.
[10] Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New England Journal of Medicine, 2008, 358(11):1160-1174.
[11] Lu J X, Peng Y, Meng Z F, et al. Rational design of an EGF-IL18 fusion protein:Implication for developing tumor therapeutics. Biochemical & Biophysical Research Communications, 2005, 334(1):157-161.
[12] Brooke J S, Cha J H, Eidels L. Latent transforming growth factor β-binding protein-3 and fibulin-1C interact with the extracellular domain of the heparin-binding EGF-like growth factor precursor. Bmc Cell Biology, 2002, 3(5):856-860.
[13] Lv Q, Yang X Z, Fu L Y, et al. Recombinant expression and purification of a MAP30-cell penetrating peptide fusion protein with higher anti-tumor bioactivity. Protein Expression & Purification, 2015, 111:9-17.
[14] Fang E F, Zhang C Z Y, Wong J H, et al. The MAP30 protein from bitter gourd (Momordicacharantia) seeds promotes apoptosis in liver cancer cells in vitro, and in vivo. Cancer Letters, 2012, 324(324):66-74.
[1] 石鹏程, 纪晓俊. 酵母系统表达人表皮生长因子研究进展 *[J]. 中国生物工程杂志, 2021, 41(1): 72-79.
[2] 卢钟腾,呼高伟. 新型细胞穿膜肽的鉴定方法与其在抗肿瘤治疗中的应用[J]. 中国生物工程杂志, 2019, 39(12): 50-55.
[3] 夏艳梅,于思远,杨晗,李廷栋. 细胞穿膜肽介导生物大分子入胞机制研究进展 *[J]. 中国生物工程杂志, 2019, 39(10): 82-89.
[4] 李文,陈洁,胡伟男,漆亚云,付毅红,刘佳敏,王贞超,欧阳贵平. EGFR耐药突变及其小分子抑制剂研究进展 *[J]. 中国生物工程杂志, 2019, 39(10): 97-104.
[5] 李思,翟逸舟,陆玉婷,王富军,赵健. 一种用于肿瘤药物治疗的新型人源性穿膜肽的优化及其应用 *[J]. 中国生物工程杂志, 2018, 38(7): 40-49.
[6] 高鑫,韦攀健,闫卓红,易玲,王小珏,杨斌,张洪涛. 一株针对人EGFR的单链抗体克隆与哺乳细胞表达 *[J]. 中国生物工程杂志, 2018, 38(5): 73-78.
[7] 李敏, 吴日伟. 抗肿瘤药物市场概述[J]. 中国生物工程杂志, 2017, 37(4): 125-133.
[8] 庞实锋, 姜潮, 李文荣, 冯治国, 刘敏, 楚生辉, 李校堃, 郑克勤. 大豆油体与EGF融合基因的克隆及其在红花种子中的表达[J]. 中国生物工程杂志, 2014, 34(4): 71-77.
[9] 王志明, 高健, 李耿. 治疗性单克隆抗体药物的现状及发展趋势[J]. 中国生物工程杂志, 2013, 33(6): 117-124.
[10] 邢雅玲, 任乐宁, 陈晓娟, 陈忠斌. 人Toll样受体靶向药物研究进展[J]. 中国生物工程杂志, 2010, 30(10): 60-65.
[11] 邢雅玲 任乐宁 陈晓娟 陈忠斌. 人Toll样受体靶向药物研究进展[J]. 中国生物工程杂志, 2010, 30(10): 0-0.
[12] 周敏 石必枝 顾健人 李宗海. 抗EGFRvIII噬菌体抗体库的构建和筛选[J]. 中国生物工程杂志, 2010, 30(04): 1-7.
[13] 张海淼 刘孝菊 田海山 万晓珊 邓林 李校堃. 人表皮生长因子融合蛋白的表达及纯化工艺的优化[J]. 中国生物工程杂志, 2010, 30(03): 74-78.
[14] 丁锡申. 基因工程药物在国内的开发情况[J]. 中国生物工程杂志, 1995, 15(4): 46-47.
[15] 汪恩浩. 面向二十一世纪的深圳现代生物技术产业[J]. 中国生物工程杂志, 1994, 14(5): 28-28.
主管：中国科学院 　主办：中国科学院文献情报中心 　中国生物技术发展中心 　中国生物工程学会